ReviewCurrent infectious disease reports2017
Opportunistic Invasive Mycoses in AIDS: Cryptococcosis, Histoplasmosis, Coccidiodomycosis, and Talaromycosis.
Review in Current infectious disease reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Treating progressive disseminated histoplasmosis in people living with HIV.The Cochrane database of systematic reviews · 2020Pooled it
- Trends in Incidence and Risk Factors of HIV-Associated Disseminated Histoplasmosis in the Americas: An Observational Cohort Study.Journal of the International AIDS Society · 2026Observational
- Two new clinical diagnostic models for Talaromycosis marneffei in AIDS patients within 48 h: evaluation of performance and comparison with previous models.BMC infectious diseases · 2026Article
- Clinical Characteristics, Management, and Outcomes of Patients Living with HIV and Coinfected withInfection and drug resistance · 2026Article
- Enhancing mortality prediction in AIDS and disseminatedJournal of medical microbiology · 2025Article
- Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.Infectious diseases and therapy · 2025Article
- The role of mNGS in the diagnosis of talaromycosis and case series.BMC infectious diseases · 2025Article
- Voriconazole Steady-State Trough Concentrations and Clinical Outcomes in Patients with Talaromycosis.Mycopathologia · 2025Article
- Status and outlook of pulmonary tuberculosis coinfection.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Disseminated histoplasmosis and presumptive CNS toxoplasmosis-associated immune reconstitution inflammatory syndrome in a patient with HIV/AIDS: a case report.BMC infectious diseases · 2024Article
- Talaromycosis from Wuhan: two-case report and literature review.Frontiers in cellular and infection microbiology · 2024Review
- Coexisting of Primary Central Nervous System Lymphoma andInfection and drug resistance · 2024Article
- Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report.Journal of medical case reports · 2022Article
- A baseline epidemiological study of the co-infection of enteric protozoans with human immunodeficiency virus among men who have sex with men from Northeast China.PLoS neglected tropical diseases · 2022Article
- Talaromyces marneffei Mp1p Antigen Detection may Play an Important Role in the Early Diagnosis of Talaromycosis in Patients with Acquired Immunodeficiency Syndrome.Mycopathologia · 2022Article
- Diagnosis by metagenomic next-generation sequencing of aFrontiers in pediatrics · 2022Article
- HIV-infected patients rarely develop invasive fungal diseases under good immune reconstitution after ART regardless high prevalence of pathogenic filamentous fungi carriage in nasopharynx/oropharynx.Frontiers in microbiology · 2022Article
- Coccidioidal meningitis and neurosyphilis co-infection in a non-HIV patient.Medical mycology case reports · 2021Article
- Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts.Diagnostics (Basel, Switzerland) · 2021Review
- Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe goal of this review is to provide an update on the epidemiology, diagnosis, and treatment of opportunistic fungal infections in patients with human immunodeficiency virus (HIV) infection including Cryptococcus spp., Histoplasma spp., Coccidioides spp., and Talaromyces marneffei, formerly Penicillium marneffei. RECENT
findingsIn many settings, despite increasing roll out of antiretroviral therapy (ART), opportunistic invasive mycoses produce a substantial burden of disease. The prevalence of specific fungal pathogens depends on their endemicity. Viral suppression achieved by greater access to ART and increased the availability of point-of-care testing with rapid diagnostic tests (RDTs) aid to curtail the associated fungi morbidity. RDTs allow earlier screening to preemptively initiate treatment of opportunistic fungal pathogens. Identifying asymptomatic cryptococcal infection before starting ART is crucial in reducing the risk of the immune reconstitution inflammatory syndrome (IRIS). There is an urgent need to decrease the burden of opportunistic invasive fungal infections in individuals with HIV/AIDS through different interventions: (a) continue to expand the deployment of ART to the most affected populations to achieve viral suppression; (b) ensure early diagnosis of fungal pathogen with point-of-care testing;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.